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Abstract
Background: The standard treatment of the axilla in breast cancer used to be an axillary lymph
node dissection. An axillary lymph node dissection is known to give substantial risks of morbidity.
In recent years the sentinel node biopsy has become common practice. Future randomized study
results will determine whether the expected decrease in morbidity can be proven.
Methods: Before the introduction of the sentinel node biopsy, we conducted a study in which 180
women of 50 years and older with T1/T2 cN0 breast cancer were treated with breast conserving
therapy. Instead of an axillary lymph node dissection regional radiotherapy was given in
combination with tamoxifen (RT-group). The study group was compared with 341 patients, with
the same patient and tumour characteristics, treated with an axillary lymph node dissection (S-
group).
Results: The treatment groups were comparable, except for age. The RT-group was significantly
older than the S-group. The median follow up was 7.2 years. The regional relapse rates were low
and equal in both treatment groups, 1.1% in RT-group versus 1.5% in S-group at 5 years. The overall
survival was similar; the disease free survival was significant better in the RT-group.
Conclusion: Regional recurrence rates after regional radiotherapy are very low and equal to an
axillary lymphnode dissection.
Background
Before the introduction of the sentinel node biopsy, the
standard treatment of the axilla in early stage breast cancer
was an axillary lymph node dissection (ALND). An ALND
results in a high risk of morbidity, while in 70% of the
postmenopausal patients with early stage breast cancer an
ALND would be unnecessary because of the absence of
lymph node metastases [1-4]. Lymph oedema of the arm
(2–28%) [4-6] and shoulder function impairment (5–
Published: 30 October 2007
Radiation Oncology 2007, 2:40 doi:10.1186/1748-717X-2-40
Received: 19 June 2007
Accepted: 30 October 2007
This article is available from: http://www.ro-journal.com/content/2/1/40
© 2007 Spruit et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
Radiation Oncology 2007, 2:40 http://www.ro-journal.com/content/2/1/4019%) [4] are most debilitating but even more patients suf-
fer from dysesthesia and pain (23–31%) [6-8].
An alternative to an ALND is primary regional radiother-
apy. This is expected to give less morbidity: arm oedema
to a lesser extent (0–9%) and shoulder function impair-
ment (0–1%) [4,9] are noted. Dysesthesia and pain are
neither mentioned nor expected.
It is always a challenge to find alternative treatments lead-
ing to less complaints but this may not lead to major
changes in tumour control and survival rates.
This study was initiated under the assumption that the
control rates and survival after regional radiotherapy
instead of an ALND in breast cancer patients of 50 years
and older, are comparable while the morbidity is less,
resulting in a better quality of life.
Methods
Patient population
Over the period 1991–2000 women aged 50 years and
older with T1 or T2 breast cancer, with clinically negative
axilla (cN = 0, assessed by physical examination) diag-
nosed in the Deventer Hospital were treated with axillary
radiotherapy instead of an ALND. If the patients preferred
the standard treatment (ALND), this was given. To com-
pare the study group, a control group was compiled from
all patients treated in the Gelre Hospitals Apeldoorn, over
the same period with the same patient and tumour char-
acteristics, and the patients from the Deventer Hospital
not treated within the study protocol. Both patient groups
were retrieved by using the regional cancer registry of the
Comprehensive Cancer Centre Stedendriehoek Twente. In
this population based cancer registry all newly diagnosed
malignancies are registered. All charts were reviewed by
the radiation oncologists of our department, concerning
patient and tumour characteristics, recurrences and sur-
vival. All TNM stages were converted into the latest ver-
sion (sixth edition) [10].
Treatment
Patients treated with lumpectomy without an ALND (RT-
group), were irradiated on the breast, the axillary, supra-
and infraclaviculary lymph nodes and the ipsilateral inter-
nal mammary chain. The radiotherapy started within 6
weeks after surgery. All patients were irradiated on the
breast with 2 tangential fields on a linear accelerator with
6 or 10 MV photon beams. Total dose to the entire breast
was 50 Gy, in 2 Gy fractions, followed by a boost at the
tumour bed of 14 Gy. Irradiation of the axilla was per-
formed with the so-called McWirther technique to prevent
overlap with the tangential fields of the breast: supracla-
vicular and axillar with two ventrodorsal opposed half-
beam fields, 6 MV photon beams, the medial part only
from ventral, specified at 3 cm. The internal mammary
chain was irradiated with a single ventrodorsal beam, 26
Gy with a 6 MV photon energy beam followed by 24 Gy
12 MeV electrons. In individual cases the internal mam-
mary chain was not irradiated as a result of the physician's
opinion based on age of the patient, tumour characteris-
tics (like size) or localisation of the tumour (lateral part of
the breast).
Although the receptor status was unknown in most
patients, adjuvant hormonal treatment, i.e. tamoxifen 20
mg a day, was given to all patients. The duration of the
hormonal treatment was at least 2 years. Evolving data
during the period of the current study showed the possi-
ble benefits of extended hormonal therapy use, therefore
some patients were treated for 5 years.
Patients who underwent a lumpectomy and an ALND, a
level 1 and 2 resection, (S-group) were irradiated on the
breast, with 2 tangential fields as described above.
Depending on the pathological findings of the tumour
and the lymph nodes, regional radiotherapy and adjuvant
therapy (hormonal and/or chemotherapy) were given
according to the National guidelines. These patients were
irradiated on the internal mammary lymph nodes in case
of a positive axilla and/or a tumour in the medial part of
the breast. When the EORTC trial investigating the role of
irradiation of the internal mammary lymph nodes [11]
was initiated, the patients were only irradiated on this
chain within the participation of this trial (16 patients of
the S-group participated in this trial).
Follow-up
For all selected patients the follow-up was completed by
performing a chart review.
All patients were followed every 3 months in the first year,
every six months from the second to the tenth year, by the
radiation oncologist alternated with the surgeon. With
every visit the patient was checked for locoregional recur-
rence, signals for distant metastases and side effects.
Unfortunately no validated morbidity lists were used so a
reliable overview of differences in morbidity can not be
given. Every year a mammography was made. After 10
years of disease free follow-up, the patients were dis-
charged.
If information about follow-up was lacking in the patient
file, general practitioners were contacted.
Statistical analysis
Differences between the two treatment groups were deter-
mined using a chi-squared test. Disease free survival and
overall survival were calculated, using multivariate Cox
regression in SPSS (Statistical Package for Social Sciences).Page 2 of 6
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first local recurrence, regional recurrence or metastasis. All
deaths, irrespective of cause of death, were taken as end-
point in the overall survival. Patients without an endpoint
were censored at the end of their follow-up in the survival
analysis. The effect of the treatment (RT or surgery) was
adjusted for the variables tumour stage pT, age and irradi-
ation of the internal mammary chain. P-value <0.05 was
considered to be statistical significant.
Results
In total 524 patients were selected from the cancer regis-
try, 3 patients were lost to follow up. Of the 521 patients
evaluated, 180 were treated within the RT-group protocol.
Three hundred and forty-one patients were treated with an
ALND. In table 1 characteristics of both patient groups are
shown. The difference in age between both groups was
significant (p < 0.001). The median follow-up was 7.2
years (mean 7.7 years). The treatment characteristics are
shown in table 2.
After 5 years, the number of regional recurrences was very
low and no differences were found between the 2 treat-
ment groups, two (1.1%) in the RT-group and five (1.5%)
in the S-group. In the RT-group one regional recurrence
was found in the supraclavicular region and the other
combined infraclavicular/axillar. In the S-group they were
located in the supraclavicular region and the axilla in 2
cases each and one combined supraclavicular/axillar.
After dissemination research two of these patients (1 in
each group) showed distant metastasis.
The local control rates were better in the RT-group, with
local recurrence rate of 2.2% and 3.5% at 5 years in the RT
and the S-group respectively. Distant failures occurred less
often in the RT-group: 6.7% vs.10.3%.
The overall survival (OS) was similar in both groups. The
5 and 10-year OS rates in the RT-group were 92% and
80%, in the S group these were 90% and 75% respectively,
figure 1.
The disease free survival (DFS) was better in the RT-group,
with a Hazard Ratio of 0.4 (95% CI: 0.3 – 0.8, p = 0.003)
in the univariate analysis and 0.4 (95% CI: 0.2 – 0.7, p =
0.001) in the multivariate analysis corrected for age, stage
and radiotherapy of the internal mammary chain, table 3;
figure 2.
Discussion
The main issue of this article is the regional control in
patients of 50 years and older with T1–2 cN0 breast cancer
treated with breast conserving therapy and regional radio-
therapy compared to an axillary lymph node dissection.
The low regional recurrence rates in our study show that
RT is a safe alternative for an ALND.
It is hard to draw firm conclusions in this non-rand-
omized setting, where selection can not be ruled out, but
some comparisons can be made.
Five studies with primary axillary radiotherapy have been
published before [1,9,12-14]. Despite the somewhat dif-
Overall survival by treatment, with numbers of patients at risk at 10 yearsFigure 1
Overall survival by treatment, with numbers of patients at 
risk at 10 years.
Table 1: patient and tumour characteristics
RT-group S-group
Number of patients 180 341
Age, years* 67 61
T stages (%) pT1 67.8 79.5
pT2 32.2 20.5





Table 2: treatment characteristics
RT-group S-group
RT axilla (%) 100% 5.9%
RT internal mammary chain (%) 78.3% 23.2%
Tamoxifen (%) 98.9% 22.3%
Chemotherapy (%) 0.6% 10.0%Page 3 of 6
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all confirm low regional recurrence rates. Compared to
these articles we have a slightly better DFS, and a higher
hormonal therapy usage, 98.9% vs. 2.4% – 71%
[9,12,13]. They also conclude that RT equals an ALND
with regard to survival, table 4.
The disease free survival was significantly better in the RT-
group, in the univariate as well as the multivariate analysis
(p < 0.05). A few explanations are possible.
The number of patients irradiated on the internal mam-
mary lymph nodes was significantly higher in the RT-
group. We cannot tell what the influence of this on the
DFS has been. Probably the results of the EORTC trial,
[11] will clarify this.
Locoregional radiotherapy, which was given to all the
patients in the RT-group, gives a better locoregional con-
trol and even a better survival in high risk postmenopau-
sal breast cancer patients [15]. Recently Overgaard
described in a subanalysis of the DBCG 82 b&c trial that
intermediate risk patients (1–3 positive lymph nodes)
benefit from locoregional radiotherapy, not only for loco-
regional control but also for survival [16]. It can be
assumed that the percentage of positive axillary lymph
nodes would be similar in both groups. Therefore it is very
well possible that the RT-group contains patients (23%)
that would have been classified as intermediate risk breast
cancer. Whether this explains the better DFS in our study
group is hard to tell. In October 2006 an EORTC study
started to give answers on that matter too (SUPREMO)
[17].
On the other hand, there are some reports showing that
no treatment of the axilla at all in early breast cancer, is an
option too [18-20]. These studies treated patients with
higher age (>70 yr) and/or smaller tumours (< 1.2 cm)
than we did. The tamoxifen usage was at least 90% in all
of them. The axillary recurrences rates in these studies var-
ied from 1,5% to 5.4%.
Tamoxifen was prescribed to all patients in the RT-group.
Literature shows that tamoxifen not only diminishes the
amount of distant failures but the local recurrences as well
[21]. It could be that this explains the differences in local
and distant failures between our two groups.
As mentioned before no reliable evaluation of the compli-
cations like lymph oedema or shoulder impairment could
be made.
The last few years the sentinel node procedure seems to
have proven its value. In the Netherlands staging of the
axilla in low risk breast cancer is routinely performed by
the SNP. Because the sentinel node biopsy is less invasive,
it gives less morbidity than an ALND. If the sentinel node
is tumour negative no further treatment of the axilla is
Disease free survival by treatment, with numbers of patients at risk at 10 yearsFigure 2
Disease free survival by treatment, with numbers of patients 
at risk at 10 years.
Table 3: results of univariate and multivariate analysis of disease free survival
Univariate Multivariate
Factor No HR 95% CI HR 95% CI
S-group 341 1 Reference 1 Reference
RT-group 180 0.4 0.3–0.8 0.4 0.2–0.7
RT internal mammary chain
Yes 220 1 Reference 1 Reference
No 301 1.0 0.7–1.6 0.7 0.4–1.1
pT1 393 1 Reference 1 Reference
pT2 128 1.6 1.0–2.6 1.8 1.1–2.8
Age 521 1.0 0.9–1.0 1.0 0.9–1.0Page 4 of 6
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needs to be treated, either with an ALND or with radio-
therapy [22]. The combination of a SNP and axillary radi-
otherapy will probably not lead to substantial morbidity,
as we see after an ALND in combination with radiother-
apy of the axilla.
It is to be expected that in the future an ALND will be of
lesser importance in the staging of breast carcinoma, espe-
cially with the upcoming techniques like Her2-neu expres-
sion and genomics. Together with the findings in the
sentinel node the indication for adjuvant therapy will be
determined. A randomized multicentre trial is investigat-
ing the difference between an ALND and axillary, supra-
and infraclaviculary radiotherapy in patients with a posi-
tive sentinel node biopsy (AMAROS trial) [23].
Conclusion
Regional recurrence rates after regional radiotherapy are
very low and can safely replace surgery in a clinically neg-
ative axilla.
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